Asia Pacific Colorectal Cancer Market Segmented By Diagnosis (Digital Rectal Examination, Fecal Occult Blood Test, Flexible Sigmoidoscopy, Colonoscopy, Virtual Colonoscopy), Treatment & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of Asia Pacific)

ID: 561
Pages: 292

Market Size, 2025

$3,630.00 Mn

Market Estimate, 2026

$3,750.00 Mn

Market Forecast, 2034

$4,900.00 Mn

CAGR, 2026–2034

3.40%

Executive Summary: Asia Pacific Colorectal Cancer Market

  • Market Scope: Comprehensive regional analysis of the Asia Pacific colorectal cancer sector, detailing diagnostic modalities, therapeutic treatment options, clinical end-users, and country-level adoption profiles.
  • Market Valuation: Valued at USD 3,630 million in 2025, reaching USD 3,750 million in 2026, and projected to expand to USD 4,900 million by 2034, growing at a steady CAGR of 3.40% from 2026 to 2034.
  • Primary Growth Drivers: Rising prevalence of colorectal cancer due to poor dietary habits and obesity, expanding geriatric population, increasing clinical trials for novel therapeutics, and rising awareness programs organized by public and private healthcare establishments.

Key Market Segment Metrics

CategoryLeading Segment (Base Position)Fastest-Growing / High-Growth Segment
By DiagnosisColonoscopy (held the largest market share, driven by high clinical accuracy, gold-standard visualization, and early detection efficacy)Fecal Occult Blood Test & Genetic Testing (projected to register high growth propelled by non-invasive screening convenience and early biomarker profiling)
By TreatmentSurgery and Radiation Therapy (dominated the base market position supported by primary tumor resection protocols and established clinical guidelines)Targeted Therapies & Immunotherapies (growing at the fastest CAGR fueled by precision medicine, biological treatments, and metastatic cancer management)
By End UsersHospitals & Specialty Oncology Centers (captured the primary market share backed by advanced surgical suites, oncology departments, and diagnostic infrastructure)Diagnostic Laboratories & Outpatient Screening Clinics (expanding steadily driven by preventive healthcare drives and screening adoption)
By CountryChina & India (market leaders with the highest regional shares, backed by massive patient populations, rising healthcare spending, and government cancer initiatives)Japan, South Korea & Southeast Asia (witnessing solid growth propelled by advanced government-backed screening programs and high medical technology access)

Major Market Players & Industry Landscape

Market Structure: Highly competitive landscape characterized by major global diagnostics and pharmaceutical corporations expanding clinical pipelines, diagnostic technologies, and regional distribution networks across Asia-Pacific.

Key Companies: Abbott Diagnostics, Hoffmann La Roche, Beckman Coulter, Alere, and Clinical Genomics.

To learn more about this report, icon Download Free Sample Report

Asia Pacific Colorectal Cancer Market Size

The Asia Pacific Colorectal Cancer Market size was valued at USD 3,630 million in 2025 and is anticipated to reach USD 3,750 million in 2026 from USD 4,900 million by 2034, growing at a CAGR of 3.40% during the forecast period from 2026 to 2034

Y-O-Y growth in the prevalence of colorectal cancer in this region, the rising number of new product releases, and the benefits of generic medicines primarily contribute to the Asia Pacific colorectal cancer market. The market is expected to expand due to the rising prevalence of colorectal cancer due to people's poor eating habits and irregular food intake schedules. These variables increase a person's chance of tumor development, which can lead to cancer. The total market is expected to improve as the elderly population grows and the number of clinical studies to bring new medications to market grows. Low-fiber diets, obesity, alcohol and cigarette use, and other variables all have a role. Compared to chemotherapy-only therapy, targeted medicines have already begun to lengthen the lives of metastatic colorectal cancer patients. Hormone treatment, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, signal transduction inhibitors, and toxin delivery agents are all forms of target therapy. Colon cancer genetic testing improves the chances of early detection. Therefore, the medical community strongly recommends it. Outside of research facilities, testing for the genes that cause colon cancer is only being started. If these medical tests are adopted, the number of instances of colon cancer detected early will rise.

In the next years, the Asia Pacific colorectal cancer market is projected to be fuelled by expanding emerging markets in developing nations. Colorectal cancer affects the colon, intestine, and rectum and is one of the most prevalent and fatal tumors caused by a combination of hereditary and environmental factors. It is the second most common cause of death in women and the third most common in males. Additionally, the colorectal cancer market is being fuelled by a growth in the prevalence population, a future product pipeline, and increased cancer preventive activities. Despite the available alternatives, only around 35% of the target population for both types of cancer participate. The rising prevalence of cancer and the availability of screening techniques are projected to propel the colorectal cancer market in the Asia Pacific to greater levels over the forecast period.

The market's expansion is predicted to be restricted by pricing pressure on drug producers. In addition, the high cost of colorectal cancer treatments and a lack of awareness in low-income countries are expected to restrict the market growth in the near future.

Lifestyle changes have also been shown to be effective in the prevention of colorectal cancer in observational studies. Colorectal cancer surgery is currently the most effective therapy option. Chemotherapy has relatively minor survival advantages. As a result, there is much confusion and disagreement regarding the costs and chances of survival. The colorectal medicines industry is being held back by the growing use of biologics and targeted treatments. Instead of chemical medicines that weaken the immune system, biological treatment employs the body's own immune system to combat cancer.

REPORT COVERAGE

REPORT METRIC

DETAILS

Market Size Available

2025 to 2034

Base Year

2025

Forecast Period

2026 to 2034

CAGR

3.4%

Segments Covered

By Diagnosis, Treatment and Region

Various Analyses Covered

Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Countries Covered

India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, the Philippines, Indonesia, Singapore, and the Rest of APAC.

Market Leaders Profiled

Abbott Diagnostics, Alere, Beckman Coulter, Clinical Genomics, Companion Dx, Hoffmann La Roche, Debiopharm Group, and Vaccinogen BD.

 

REGIONAL ANALYSIS

Regionally, the Asia Pacific region is projected to grow at the highest CAGR during the forecast period due to the rising aging population and increasing participation of several private & public establishments to organize awareness programs on Colorectal Cancer. China is the largest market for Colorectal Cancer in this region, followed by India. In addition, Indonesia, Vietnam, and Malaysia are some of the significant players in this market.

The market for colorectal cancer diagnostics and treatments in Asia Pacific is anticipated to develop rapidly in the coming years, with China and India leading the way. For decades, cancer has been a leading cause of mortality in Japan. The Japanese government has been developing and implementing several projects and programs to improve cancer treatment quality and raise cancer awareness. The market in this area has grown due to increased government funding for colorectal cancer surgical methods and medicines. In addition, new technological advancements, FDA approval of new medications, and important competitors in the market are contributing to the industry's growth.

KEY MARKET PLAYERS

A few promising companies in the APAC Colorectal Cancer Market include

  • Abbott Diagnostics
  • Alere
  • Beckman Coulter
  • Clinical Genomics
  • Companion Dx
  • Hoffmann La Roche
  • Debiopharm Group
  • Vaccinogen BD

MARKET SEGMENTATION

This research report on the APAC Colorectal Cancer Market has been segmented and sub-segmented into the following categories.

By Diagnosis

  • Digital Rectal Examination
  • Fecal Occult Blood Test
  • Flexible Sigmoidoscopy
  • Colonoscopy
  • Virtual Colonoscopy

By Treatment

  • Surgery and Radiation Therapy
  • Chemotherapy
  • Targeted Therapies
  • Resistance to Pharmacological Therapies

By Country

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Trusted by 500+ companies. We respect your privacy and never share your data.

Please wait. . . . Your request is being processed

Related Reports

Click for Request Sample